Skip to main content

Main menu

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
  • Other Publications
    • The Journal of Applied Laboratory Medicine

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Clinical Chemistry
  • Other Publications
    • The Journal of Applied Laboratory Medicine
  • Subscribe
  • My alerts
  • Log in
Clinical Chemistry

Advanced Search

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
NewsClinical Chemist

The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors

Vijayalakshmi Nandakumar, John R. Mills
DOI: 10.1373/clinchem.2018.295097 Published January 2019
Vijayalakshmi Nandakumar
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Mills
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mills.john2@mayo.edu
  • Article
  • Info & Metrics
  • PDF
Loading

Since their approval in 2014, immune checkpoint inhibitors (ICIs)2 have transformed cancer care. However, the effectiveness of these agents varies greatly among different tumor types and across individual patients. This variation is a substantial challenge for optimal use of ICIs. Several response predictors have been reported, including high drug target expression (e.g., programmed death-ligand 1), increased abundance of tumor-infiltrating lymphocytes, or the presence of mutations in DNA repair genes. Yet, each predictor has limited utility as a biomarker for patient selection. A recent article in Science describes how several promising studies have now indicated that tumor mutational burden (TMB) may succeed when other response predictors have failed and may serve as a highly predictive pan-tumor biomarker of ICI sensitivity (1).

TMB is defined as the total number of nonsynonymous …

View Full Text

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$15.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Log in using your username and password

Forgot your user name or password?
Forgot your username or password?

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
PreviousNext
Back to top

In this issue

Clinical Chemistry: 65 (2)
Vol. 65, Issue 2
February 2019
  • Table of Contents
  • About the Cover
  • Index by author
  • Table of Contents (PDF)
  • Cover (PDF)
  • Advertising (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
  • Audio summary of this issue
Print
Share
The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
Vijayalakshmi Nandakumar, John R. Mills
Clinical Chemistry Feb 2019, 65 (2) 357; DOI: 10.1373/clinchem.2018.295097
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
Vijayalakshmi Nandakumar, John R. Mills
Clinical Chemistry Feb 2019, 65 (2) 357; DOI: 10.1373/clinchem.2018.295097

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • Reference
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Clinical Chemist

  • Unexpected Pregnancy Test Results
  • Serendipity in Science: The Unexpected Tie
Show more Clinical Chemist

News & Views

  • “Reaching Out to the World” Appreciation
  • Clinical Chemistry's Invited Reviewers 2018
Show more News & Views

Similar Articles

Options

  • Home
  • About
  • Articles
  • Information for Authors
  • Resources
  • Abstracts
  • Submit
  • Contact
  • RSS

Other Publications

  • The Journal of Applied Laboratory Medicine
Footer logo

© 2019 American Association for Clinical Chemistry

Powered by HighWire